Others is under clinical development by Eyenovia and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Others’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Others overview
Eyenovia overview
Eyenovia is an ophthalmic biopharmaceutical company that discovers and develops treatments for eye diseases. The commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis in diagnostic procedures and prepares to commercialize clobetasol propionate for treating post-operative inflammation and pain following ocular surgery. Eyenovia pipeline products include MicroPine, EYEN-510, EYEN-520 and EYEN-530 for indication of pediatric myopia and dry eye. The company utilizes its Optejet technology to deliver precise microdoses of ophthalmic medications. Eyenovia is headquartered in New York, the US.
For a complete picture of Others’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
